PMC:7534795 / 1323-1786
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T15726 | 103-108 | Body_part | denotes | lipid | http://purl.org/sig/ont/fma/fma67264 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T13 | 407-415 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T53704 | 75-76 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T12 | 14-18 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
| T13 | 20-23 | Chemical | denotes | EPA | http://purl.obolibrary.org/obo/CHEBI_28364|http://purl.obolibrary.org/obo/CHEBI_36006 |
| T15 | 29-49 | Chemical | denotes | docosahexaenoic acid | http://purl.obolibrary.org/obo/CHEBI_36005 |
| T16 | 45-49 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
| T17 | 51-54 | Chemical | denotes | DHA | http://purl.obolibrary.org/obo/CHEBI_16016|http://purl.obolibrary.org/obo/CHEBI_28125|http://purl.obolibrary.org/obo/CHEBI_28689|http://purl.obolibrary.org/obo/CHEBI_36005 |
| T21 | 77-82 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T22 | 103-108 | Chemical | denotes | lipid | http://purl.obolibrary.org/obo/CHEBI_18059 |
| T23 | 276-281 | Chemical | denotes | PUFAs | http://purl.obolibrary.org/obo/CHEBI_26208 |
| T24 | 292-303 | Chemical | denotes | metabolites | http://purl.obolibrary.org/obo/CHEBI_25212 |
| T25 | 338-343 | Chemical | denotes | PUFAs | http://purl.obolibrary.org/obo/CHEBI_26208 |
| T26 | 357-365 | Chemical | denotes | adjuvant | http://purl.obolibrary.org/obo/CHEBI_60809 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T10 | 227-425 | Sentence | denotes | Considering the favorable safety profile for n-3 PUFAs and their metabolites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management of COVID-19 patients. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 41 | 416-424 | Species | denotes | patients | Tax:9606 |
| 45 | 20-23 | Chemical | denotes | EPA | MESH:D015118 |
| 46 | 29-49 | Chemical | denotes | docosahexaenoic acid | MESH:D004281 |
| 47 | 51-54 | Chemical | denotes | DHA | MESH:D004281 |
| 48 | 103-108 | Chemical | denotes | lipid | MESH:D008055 |
| 49 | 272-281 | Chemical | denotes | n-3 PUFAs | MESH:D015525 |
| 50 | 334-343 | Chemical | denotes | n-3 PUFAs | MESH:D015525 |
| 61 | 407-415 | Disease | denotes | COVID-19 | MESH:C000657245 |